Hypereosinophilic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.
The Hypereosinophilic Syndrome pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects.
Hypereosinophilic Syndrome Pipeline Drugs Market Segmentation by Targets
The key targets in the Hypereosinophilic Syndrome pipeline drugs market are Interleukin 5, Cells Expressing Interleukin 3 Receptor Subunit Alpha, Interleukin 5 Receptor Subunit Alpha, Tyrosine Protein Kinase JAK1, and Tyrosine Protein Kinase JAK2.
Hypereosinophilic Syndrome Pipeline Drugs Market Analysis, by Targets
For more insights on Hypereosinophilic Syndrome pipeline drugs targets, download a free report sample
Hypereosinophilic Syndrome Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of actions in the Hypereosinophilic Syndrome pipeline drugs market are Interleukin 5 Inhibitor, Cytotoxic to Cells Expressing Interleukin 3 Receptor Subunit Alpha, Interleukin 5 Receptor Subunit Alpha Antagonist, Tyrosine Protein Kinase JAK1 Inhibitor, and Tyrosine Protein Kinase JAK2 Inhibitor.
Hypereosinophilic Syndrome Pipeline Drugs Market Analysis, by Mechanism of Actions
For more insights on Hypereosinophilic Syndrome pipeline drugs mechanism of actions, download a free report sample
Hypereosinophilic Syndrome Pipeline Drugs Market Segmentation by Key Routes of Administration
The key routes of administration in the Hypereosinophilic Syndrome pipeline drugs market are intravenous, subcutaneous, oral, inhalational, parenteral, and topical.
Hypereosinophilic Syndrome Pipeline Drugs Market Analysis, by Routes of Administration
For more insights on Hypereosinophilic Syndrome pipeline drugs routes of administration, download a free report sample
Hypereosinophilic Syndrome Pipeline Drugs Market Segmentation by Key Molecule Types
The key molecule types in the Hypereosinophilic Syndrome pipeline drugs market are monoclonal antibody, small molecule, fusion protein, and protein.
Hypereosinophilic Syndrome Pipeline Drugs Market Analysis, by Molecule Types
For more insights on Hypereosinophilic Syndrome pipeline drugs molecule type, download a free report sample
Competitive Landscape
Some of the leading companies in the Hypereosinophilic Syndrome pipeline drugs market are GSK plc, A. Menarini Industrie Farmaceutiche Riunite Srl, Areteia Therapeutics Inc, Incyte Corp, Kyowa Kirin Co Ltd, and Nexeos Bio.
Hypereosinophilic Syndrome Pipeline Drugs Market Analysis, by Companies
To know more about the leading players in the Hypereosinophilic Syndrome pipeline drugs market, download a free report sample
Hypereosinophilic Syndrome Pipeline Drugs Market Overview
Key Targets | Interleukin 5, Cells Expressing Interleukin 3 Receptor Subunit Alpha, Interleukin 5 Receptor Subunit Alpha, Tyrosine Protein Kinase JAK1, and Tyrosine Protein Kinase JAK2 |
Key Mechanism of Actions | Interleukin 5 Inhibitor, Cytotoxic to Cells Expressing Interleukin 3 Receptor Subunit Alpha, Interleukin 5 Receptor Subunit Alpha Antagonist, Tyrosine Protein Kinase JAK1 Inhibitor, and Tyrosine Protein Kinase JAK2 Inhibitor |
Key Routes of Administration | Intravenous, Subcutaneous, Oral, Inhalational, Parenteral, and Topical |
Key Molecule Types | Monoclonal Antibody, Small Molecule, Fusion Protein, and Protein |
Leading Companies | GSK plc, A. Menarini Industrie Farmaceutiche Riunite Srl, Areteia Therapeutics Inc, Incyte Corp, Kyowa Kirin Co Ltd, and Nexeos Bio |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Areteia Therapeutics Inc
GSK plc
Incyte Corp
Kyowa Kirin Co Ltd
Nexeos Bio
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Hypereosinophilic Syndrome pipeline drugs market?
The key targets in the Hypereosinophilic Syndrome pipeline drugs market are Interleukin 5, Cells Expressing Interleukin 3 Receptor Subunit Alpha, Interleukin 5 Receptor Subunit Alpha, Tyrosine Protein Kinase JAK1, and Tyrosine Protein Kinase JAK2.
-
What are the key mechanism of actions in the Hypereosinophilic Syndrome pipeline drugs market?
The key mechanism of actions in the Hypereosinophilic Syndrome pipeline drugs market are Interleukin 5 Inhibitor, Cytotoxic to Cells Expressing Interleukin 3 Receptor Subunit Alpha, Interleukin 5 Receptor Subunit Alpha Antagonist, Tyrosine Protein Kinase JAK1 Inhibitor, and Tyrosine Protein Kinase JAK2 Inhibitor.
-
What are the key routes of administration in the Hypereosinophilic Syndrome pipeline drugs market?
The key routes of administration in the Hypereosinophilic Syndrome pipeline drugs market are intravenous, subcutaneous, oral, inhalational, parenteral, and topical.
-
What are the key molecule types in the Hypereosinophilic Syndrome pipeline drugs market?
The key molecule types in the Hypereosinophilic Syndrome pipeline drugs market are monoclonal antibody, small molecule, fusion protein, and protein.
-
Which are the leading companies in the Hypereosinophilic Syndrome pipeline drugs market?
The leading companies in the Hypereosinophilic Syndrome pipeline drugs market are GSK plc, A. Menarini Industrie Farmaceutiche Riunite Srl, Areteia Therapeutics Inc, Incyte Corp, Kyowa Kirin Co Ltd, and Nexeos Bio.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.